findmyKOL
Clinical trialNCT05446298Active, not recruitingPhase 2Interventional

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

SponsorOncoC4, Inc.Enrollment58Fallopian Tube CancerHigh Grade Serous Adenocarcinoma of OvaryOvarian CancerPrimary Peritoneal Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Cancer Treatment Centers of America, Phoenix. 403

    Goodyear, Arizona, United States

  • Honor Health, Usor, 406

    Phoenix, Arizona, United States

  • Nuvance Health System, 401

    Danbury, Connecticut, United States

  • Baptist Md Anderson Cancer Center, 404

    Jacksonville, Florida, United States

  • Sudarshan Sharma, Md. Ltd. 414

    Hinsdale, Illinois, United States

  • Cancer Treatment Centers of America, Chicago. 410

    Zion, Illinois, United States

  • Northwest Cancer Centers - Dyer, in - Usor, 422

    Dyer, Indiana, United States

  • Baptist Health Lexington, 407

    Lexington, Kentucky, United States

  • Norton Cancer Institute - St. Matthews, 416

    Louisville, Kentucky, United States

  • Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409

    Shreveport, Louisiana, United States

  • Minnesota Oncology Hematology, P. A. - Usor, 421

    Maplewood, Minnesota, United States

  • Center of Hope, 413

    Reno, Nevada, United States

  • the Valley Hosptial, Inc. 411

    Ridgewood, New Jersey, United States

  • Women'S Cancer Care Associates, Llc. 405

    Albany, New York, United States

  • the Ohio State University James Cancer Center, 412

    Columbus, Ohio, United States

  • Oncology Associates of Oregon, P. C. - Usor. 419

    Eugene, Oregon, United States

  • Texas Oncology, P. A. - Austin, Usor. 417

    Austin, Texas, United States

  • Texas Oncology, P.A., Fort Worth - Usor. 420

    Fort Worth, Texas, United States

  • Texas Oncology, P. A. Woodlands - Usor, 418

    The Woodlands, Texas, United States

  • Texas Oncology - Northeast Texas - Usor, 423

    Tyler, Texas, United States

  • Medical College of Wisconsin, 408

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Dec 2022
Primary completion
30 Aug 2026
Completion
30 Aug 2026
Last update posted
13 Apr 2026
Registered enrollment
58
Registry id
NCT05446298

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.